Citadel Advisors
DWTX

Citadel Advisors’s Dogwood Therapeutics DWTX Stock Holding History

Citadel Advisors’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,712
Closed -$45K – 15568
2022
Q3 		$45K Buy
+4,712
New +$664K ﹤0.01% 11709

Other funds holding DWTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCG
McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Citadel Advisors's DWTX Position: Q3 2023 in Review

Citadel Advisors sold out of Dogwood Therapeutics (DWTX) in Q3 2023, closing a stake of 1,332 shares — an estimated $46K sold.

Citadel Advisors first reported a position in DWTX in Q2 2021 and held it in 2 quarters. The position peaked at $64K in Q2 2021. 23 funds tracked by Wall St. Rank hold DWTX as of Q3 2023.

  • Citadel Advisors reported no remaining Dogwood Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Citadel Advisors sold 1,332 Dogwood Therapeutics shares in Q3 2023, an estimated $46K.
  • Citadel Advisors first reported a position in Dogwood Therapeutics in Q2 2021 and held it in 2 quarters.
  • Citadel Advisors's Dogwood Therapeutics position peaked at $64K in Q2 2021.
  • 23 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.